Navigation Links
Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety
Date:9/27/2011

ccines, in combination with Inovio's proprietary CELLECTRA® delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
2. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
3. Inovio Pharmaceuticals to Present at Investor Conferences
4. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
5. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
6. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
7. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
8. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
9. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
10. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
11. Inovio Pharmaceuticals to Present at Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... YORK, Sept. 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0611073/Global-Intravascular-Ultrasound-IVUS-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_I This ... Ultrasound (IVUS) in US$ Million by the ...
... Pa., Sept. 8, 2011 Auxilium Pharmaceuticals, Inc. ... company, today announced additional three year recurrence data ... Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX ... of adult Dupuytren,s contracture patients with a palpable ...
Cached Medicine Technology:Global Intravascular Ultrasound (IVUS) Industry 2Global Intravascular Ultrasound (IVUS) Industry 3Global Intravascular Ultrasound (IVUS) Industry 4Global Intravascular Ultrasound (IVUS) Industry 5Global Intravascular Ultrasound (IVUS) Industry 6Global Intravascular Ultrasound (IVUS) Industry 7Global Intravascular Ultrasound (IVUS) Industry 8Global Intravascular Ultrasound (IVUS) Industry 9Global Intravascular Ultrasound (IVUS) Industry 10Global Intravascular Ultrasound (IVUS) Industry 11Global Intravascular Ultrasound (IVUS) Industry 12Global Intravascular Ultrasound (IVUS) Industry 13Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 2Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 3Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 4Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 5Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 6Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 7Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 8Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 9
(Date:7/13/2014)... Advanced boilers are preferred over ... of fossil fuels, produce high-capacity power, emit fewer ... global warming and climate change concerns, many countries ... gas emissions and pollutants coming from fossilfuel-based power ... global advance boilers market., The global power rental ...
(Date:7/13/2014)... 13, 2014 According to a ... Computing Market by Component (processor, GPU, DSP, connectivity), ... Medical), and Geography - Forecast and Analysis to ... Processing & Computing Market is expected to reach ... of 20.75% from 2014 to 2020. , Browse ...
(Date:7/13/2014)... A Massachusetts couple who have done ... associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) finally ... regulators, as they presented poignant testimony on the second ... (FDA) advisory panel meeting convened to address the issue, ... Democrat and Chronicle, Dr. Hooman Noorchashm and his wife, ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... WASHINGTON, Sept. 25 The following was,released today by ... tonight, the House of Representatives is expected to vote ... for,illegal immigrants and uses budgetary gimmicks to capture new ... private insurance and,onto government-run health care. Here,s just a ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... services, today announced that it has,filed a universal ... (SEC) for the periodic offering and sale of ... common stock and warrants,after the SEC declares the ...
... CHARLOTTESVILLE, VA (September 25, 2007) Birds, fish and ... generally cannot: re-grow damaged or lost inner ear hair ... deficiencies and disabling balance problems in an estimated 250 ... treatments, research and development efforts have been hindered by ...
... Under Medicare Creates Two-Tiered System of Cancer Care ... Face Avoidable Blood Transfusions, HOUSTON, Sept. 25 ... over 1,100 oncologists across the,country, today expressed "deep ... for Medicare and Medicaid Services (CMS) -- the ...
... American Society of,Transplantation (AST) Past President Jeffrey ... Representatives, Information, Policy, Census and,National Archives Subcommittee of ... subcommittee to use public policy and,technology to strengthen ... Dr. Crippin, over 97,000 individuals are awaiting a,life-saving ...
... Sept. 25 The HealthCentral Network,Inc. ... an author,and psychotherapist who has asthma and ... expert. Miller, dubbed,"Allergic Girl", first gained online ... Nuts", which catalogues her daily challenges with ...
Cached Medicine News:Health News:'Compromise' SCHIP Deal Substitutes Ideology for Common Sense 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 3Health News:Study expected to boost research for hearing and balance therapies 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 3Health News:American Society of Transplantation's Past President Testifies Before Congress at Forum on Organ Donation 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 3
CRP Liquid Conrtols level 3...
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Medicine Products: